期刊文献+

利拉鲁肽与胰岛素强化治疗对肥胖2型糖尿病患者的效果观察 被引量:4

Effect of Intensive Treatment with Liraglutide and Insulin on Obese Patients with Type 2 Diabetes
在线阅读 下载PDF
导出
摘要 目的对利拉鲁肽与胰岛素强化治疗对肥胖2型糖尿病患者的效果进行分析和研究。方法选择2017年12月—2018年6月该院收治的的90例肥胖2型糖尿病患者作为研究对象,随机将其划分为对照组和观察组,每组各有45例患者。采用胰岛素对对照组患者进行治疗,在此基础上采用利拉鲁肽治疗观察组,对两组患者的治疗效果进行分析和比较。结果两组患者治疗前血糖情况相比差异无统计学意义(P>0.05)。观察组治疗后的血糖情况均明显低于对照组,两组患者相比差异有统计学意义(P<0.05)。两组患者的不良反应发生率相比差异无统计学意义(P>0.05)。结论在肥胖2型糖尿病患者的临床治疗中采用利拉鲁肽与胰岛素具有很好的效果,而且安全性较高。 Objective To analyze and study the effect of intensive treatment with liraglutide and insulin on obese patients with type 2 diabetes.Methods A total of 90 obese patients with type 2 diabetes admitted to our hospital from December 2017 to June 2018 were enrolled in the study.They were randomly divided into control group and observation group,with 45 patients in each group.The patients in the control group were treated with insulin.On the basis of this,the treatment group was treated with liraglutide,and the therapeutic effects of the two groups were analyzed and compared.Results There was no significant difference in pre-treatment blood glucose between the two groups(P>0.05).The blood glucose level of the observation group was significantly lower than that of the control group,and the difference between the two groups was significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The use of liraglutide and insulin in the clinical treatment of obese patients with type 2 diabetes has a good effect and is safe.
作者 向传平 周伟 邹宏林 谭海波 周翠萍 XIANG Chuan-ping;ZHOU Wei;ZOU Hong-lin;TAN Hai-bo;ZHOU Cui-ping(Department of Endocrinology,Yidu First People's Hospital,Yidu,Hubei Province,443300 China)
出处 《糖尿病新世界》 2019年第18期189-190,共2页 Diabetes New World Magazine
关键词 肥胖型 2型糖尿病 利拉鲁肽 胰岛素 Obesity Type 2 diabetes Liraglutide Insulin
  • 相关文献

参考文献5

二级参考文献43

  • 1胡仁明,李洪超.胰高血糖素样多肽-1类药治疗2型糖尿病的复合终点评价[J].中华糖尿病杂志,2010,2(4). 被引量:16
  • 2李霞,周智广,亓海英,陈小燕,黄干.用空腹C肽代替胰岛素改良Homa公式评价胰岛素抵抗和胰岛β细胞功能[J].中南大学学报(医学版),2004,29(4):419-423. 被引量:216
  • 3Li CJ,Li J,Zhang QM,et al.Efficacy and safety comparison between liraglutide as add-on therapy to insulin and insulin doseincrease in Chinese subjects with poorly controlled type 2 diabetes and abdomi-nal obesity[J].Cardiovasc Diabetol,2012,11:142.
  • 4Hoist JJ.The physiology of glucagon-like peptidel[J].Physiol Rev,2007,87(4):1409-1439.
  • 5Drueker DJ,Nauck MA.The incretin system:glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J].Lancet,2006,368(9548):1696-1705.
  • 6Nauck MA,Meier JJ,Creutzfeldt W.Incretins and their analogues a8 new antidiabetic drugs[J].Drug News Perspect,2003,16(7):413-422.
  • 7Garber A,Henry R,Ratner R,et al.Liraglutide versus glimepiride monotherapy for type 2 diabetes(LEAD-3 Mono):a randomized,52-week,phaseⅢ,double-blind,paralleltreatment trial[J].Lancet,2009,373(56):473-481.
  • 8Marre M,Shaw J,Brandle M,et al.Liraglutide,a once-daily human GLP-1 analogue,added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes(LEAD-1 SU)[J].Diabetic Med,2009,26(8):268-278.
  • 9Nauck M,Frid A,Hermansen K,et al.Efficacy and safety comparison of liraglutide glimepiride,and placebo,all in combination with metformin,in type 2 diabetes:the LEAD(liraglutide effect and action in diabetes)-2 study[J].Diabetes Care,2009,65(3):84-90.
  • 10Hoist JJ. The physiology of glucagon - like peptide 1 [ J ]. Physiol Rev, 2007,87(4) :1409 - 1439.

共引文献129

同被引文献45

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部